secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001193125-22-151007
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences Q1 net loss $2.6M; cash $40M to fund operations for 24 months
-------------------------------------------------------------------------------

- Net loss of $2.6M ($0.17 per share) vs $4.8M ($0.36) in Q1 2021; R&D spend down to $0.7M on wind-down of FB-401.
- Cash and cash equivalents $40.0M; cash burn $2.0M in Q1; sufficient for at least 24 months.
- Lead asset FB-102 for autoimmune diseases expected to enter clinic in H2 2023.
- Appointed Stephen Doberstein, Ph.D. and Barbara Finck, M.D. to board of directors.
- 14.8M shares outstanding as of March 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522151007/0001193125-22-151007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522151007/d358978d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-151007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer